Mallinckrodt (MNK) PT Raised to $35.00
Mallinckrodt (NYSE:MNK) had its target price lifted by investment analysts at Morgan Stanley from $14.00 to $35.00 in a research report issued to clients and investors on Friday. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 0.89% from the company’s current price.
Other equities analysts have also issued reports about the company. Mizuho reaffirmed a “hold” rating and issued a $15.00 price objective on shares of Mallinckrodt in a research note on Friday, April 20th. Wells Fargo & Co boosted their price target on Mallinckrodt from $15.00 to $21.00 and gave the stock a “market perform” rating in a research report on Monday, July 9th. Piper Jaffray Companies reissued a “buy” rating and set a $39.00 price target on shares of Mallinckrodt in a research report on Wednesday, August 8th. Cantor Fitzgerald reissued a “buy” rating and set a $42.00 price target on shares of Mallinckrodt in a research report on Tuesday, August 7th. Finally, SunTrust Banks boosted their price target on Mallinckrodt to $32.00 and gave the stock a “positive” rating in a research report on Monday, August 13th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have assigned a buy rating to the company’s stock. Mallinckrodt has a consensus rating of “Hold” and an average price target of $32.63.
NYSE MNK opened at $34.69 on Friday. The stock has a market capitalization of $2.59 billion, a PE ratio of 4.63, a PEG ratio of 0.48 and a beta of 1.36. Mallinckrodt has a 1-year low of $11.65 and a 1-year high of $41.70. The company has a current ratio of 2.27, a quick ratio of 2.06 and a debt-to-equity ratio of 0.98.
Institutional investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. acquired a new position in shares of Mallinckrodt in the 1st quarter valued at approximately $104,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Mallinckrodt by 11,188.0% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 10,385 shares of the company’s stock valued at $150,000 after purchasing an additional 10,293 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new position in shares of Mallinckrodt in the 1st quarter valued at approximately $175,000. Financial Gravity Wealth Inc. acquired a new position in shares of Mallinckrodt in the 1st quarter valued at approximately $182,000. Finally, Advisors Preferred LLC raised its position in shares of Mallinckrodt by 493.9% in the 2nd quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock valued at $196,000 after purchasing an additional 8,742 shares in the last quarter.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Further Reading: Trading Strategy
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.